Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871882 · ClinicalTrials.gov registry record · Phase 2
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02871882: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02871882 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871882, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipeptidyl peptidase-4) inhibitors (e.g. sitagliptin) alone or in combination with metformin.
Interventions
- OTHER Placebo
- RADIATION Gastric Emptying test
- OTHER Mixed Oral Glucose Tolerance test
- DRUG Conjugated bile acids sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871882
The ClinicalTrials.gov registry entry for NCT02871882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02871882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871882 about?
NCT02871882 is a clinical study titled "Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus". To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipep...
What is the current status of trial NCT02871882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-09-15. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT02871882?
The interventions under investigation include: Placebo (OTHER), Gastric Emptying test (RADIATION), Mixed Oral Glucose Tolerance test (OTHER), Conjugated bile acids sodium (DRUG).
Who is sponsoring clinical trial NCT02871882?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.